Cost-effectiveness of Bezlotoxumab Compared With Placebo for the Prevention of Recurrent Clostridium difficile Infection.
published in: Clinical Infectious Diseases
date of publication: 2017-11-02
language: English
main subject: Clostridium difficile, placebo
Cites articles
There is nothing here
Article - wd:Q50140886